Lund - Alligator Bioscience (Nasdaq Stockholm: ATORX) announces that the company will participate in Redeyes Fight Cancer Seminar 2021 today, January 21, where CEO Per Norlen will provide an operational update and a deeper insight into the company's focus on clinical development programs.

Alligator Bioscience presents at 13:25. The presentation is broadcast live and can be followed at https://www.redeye.se/events/801699/fight-cancer-2020 where the presentation will also be available afterwards. The presentation will also be available afterwards on Alligator's website http://www.alligatorbioscience.com.

Contact:

Cecilia Hofvander

Tel: 046-540 82 06

Email:cecilia.hofvander@alligatorbioscience.com

About Alligator Bioscience

Alligator Bioscience is a public Swedish biotechnology company that develops tumor-targeted immunotherapies for cancer. Alligator's project portfolio focuses on the two priority drug candidates ATOR-1017 and mitazalimab. In addition, two projects are conducted through collaboration agreements; ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development through Shanghai Henlius Inc. The company has also recently developed a new concept for patient-specific immunotherapy, Neo-X-Prime. Alligator's shares are traded on Nasdaq Stockholm under the ticker 'ATORX'. The head office is located at Medicon Village in Lund, Sweden.

(C) 2021 Electronic News Publishing, source ENP Newswire